- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02629627
Conjugated Linoleic Acid / Leucine Versus Metformin on Visceral Fat in Metabolic Syndrome
Effect of the Administration of Conjugated Linoleic Acid / Leucine Plus Metformin on Visceral Fat in Patients With Metabolic Syndrome
In Mexico, obesity is a major public health problem. In recent years he has presented a considerable increase in the population. As a result, it has triggered a proportional increase in the incidence of cardiovascular disease and the development of Metabolic Syndrome (METS). Abdominal obesity is one of the main components of METS which is generally associated with insulin resistance / hyperinsulinemia. This is influenced both by the subcutaneous adipose tissue as visceral adipose tissue. There is evidence that the visceral fat has an important bearing on many factors of METS, like: glucose intolerance, hypertension, dyslipidemia, and insulin resistance.
For management it requires a multidisciplinary approach, including changes in lifestyle, psychological and nutritional intervention as well as pharmacological and non-pharmacological support.
Among non-pharmacological therapies, there is recently the use of Conjugated Linoleic Acid (ACL) and leucine where in its assigned properties include weight reduction, anti-atherogenic , hypocholesterolemic and immunostimulant effect and anticarcinogenic properties. Regarding weight reduction dominates the mechanism of action anti-lipolytic effect. But, studies are needed to link this consumption with the increase or decrease on visceral fat in individuals with METS.
Study Overview
Status
Conditions
Detailed Description
The main objective is to compare the effect of the administration of ACL/Leucine vs. Metformin on visceral fat area in patients with METS. We will conduct a double-blind trial, randomized, on 4 groups, each group with 26 male and female patients of 35-65 years of age with METS diagnosed by IDF criteria. Randomization will determine who will receive the intervention during 8 week trial, each group will be like:
Group (A) intervention with ACL/Leucine plus Metformin: 26 individuals will receive ACL/Leucine in a dosis of 2,475mg per 24 hrs (1,650mg or 2 capsules with the first meal and 825 mg or 1 capsule with the second meal) plus Metformin in a dose of 500 mg per day (with the first bite of the second meal) during 8 weeks.
Group (B) Metformin plus Placebo of ACL/Leucine: 26 individuals will receive Metformin in a dose of 500 mg per day (with the first bite of the second meal) plus homologue placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 8 weeks.
Group (C) ACL/Leucine plus Metformin's Placebo: 26 individuals will receive ACL/Leucine in a dose of 2,475mg per 24 hrs (1,650mg or 2 capsules with the first meal and 825 mg or 1 capsule with the second meal) plus homologate placebo of metformin (calcined magnesia) in a dose of 500 mg per day (with the first bite of the second meal) during 8 weeks.
Group (D) Placebo of ACL/Leucine plus Placebo of Metformin: homologate placebo of ACL/Leucine (linseed oil capsules) in a dose of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) plus homologated placebo of metformin (calcined magnesia capsules) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks.
The clinical findings and laboratory test include a metabolic profile and biosafety, which will be baseline and at 8 weeks.
Visceral fat area, epicardial fat, body weight, body fat, body mass index (BMI) and blood pressure will be determined during the inicial and final visit, likewise, hemodynamics parameters of arterial stiffness like aortic pulse wave velocity (PWVao), central pulse pressure (PPao), aortic augmentation index (IAxao) and central systolic blood pressure (cSBP) by an oscillometric monitoring system via BPLab ®. Adverse events and adherence to treatment will be documented. Statistical analysis: Mann-Whitney U Test and Wilcoxon exact test. It is considered with significance at p<0.05.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Diagnosis of metabolic syndrome by IDF criteria:
- Central obesity (defi ned as waist circumference* with ethnicity specifi c values)≥80 cm in females and ≥90 cm in males
plus any two of the following four factors:
- Raised triglycerides ≥ 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality Reduced HDL colesterol
- < 40 mg/dL (1.03 mmol/L) in males < 50 mg/dL (1.29 mmol/L) in females or specifi c treatment for this lipid abnormality
- Raised blood pressure systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment of previously diagnosed hypertension
Raised fasting plasma glucose (FPG) ≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes
- Stable body weight in the last 3 months
- Written informed consent
Exclusion Criteria:
- Ascitis
- With previous abdominal surgery
- Pathologies that course with abdominal wall edema fluid retention
- Paniculitis of reumatic origin or any other ethiology
- Reumatic pathologies
- Metalic prothesis
- Previous known allergy to any of the ingredients that make up the active treatments assigned
- Known problem of fat absortion, esteatorrea, lipase deficiency, malabsortion of intestinal problems, CUCI
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: cojugated ALC/Leucine+Metformin
Intervention with conjugated linoleic acid/Leucine + 500mg in individuals with METS
|
Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal during 12 weeks.
Other Names:
Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks
Other Names:
|
Active Comparator: Metformin+placebo conjugatedALC/leucine
active comparator with Metformin 500mg + Placebo of ACL/Leucine in individuals with METS
|
Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks
Other Names:
Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 12 weeks.
Other Names:
|
Placebo Comparator: Placebo of Metformin
Active comparator with ACL/Leucine + Placebo of Metformin in individuals with METS
|
Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal during 12 weeks.
Other Names:
homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
Other Names:
|
Placebo Comparator: ACL/Leu placebo
Placebo comparator with ACL/Leu placebo + Metformin placebo in individuals with METS
|
Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 12 weeks.
Other Names:
homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in visceral fat area messure in centimers ^2 at 8 weeks
Time Frame: baseline and 8 weeks
|
Before and after intervention using a visceral fat monitor Omron's dual impedance analysis method scan HDS-2000
|
baseline and 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
2. Change from Baseline epicardial fat area messure in milimeters ^2 at 8 weeks
Time Frame: baseline and 8 weeks
|
Before and after intervention with ecocardiogragh imagic master of Kontron Medical.
|
baseline and 8 weeks
|
1. Change from Baseline in weight expressed in kg at 8 weeks
Time Frame: baseline and 8 weeks
|
Before and after intervention using a tetrapolar bioelectrical impedance analyzer (body composition analyzer TBF-215 - Tanita)
|
baseline and 8 weeks
|
Change from baseline in Body Mass Index, expressed in kg/m^2 at 8 weeks
Time Frame: baseline and 8 weeks
|
before and after intervention using a tetrapolar bioelectrical impedance analyzer (body composition analyzer TBF-215 - Tanita)
|
baseline and 8 weeks
|
Change from baseline in Total Tody Fat, expressed in percentage at 8 weeks
Time Frame: baseline and 8 weeks
|
before and after intervention using a tetrapolar bioelectrical impedance analyzer (body composition analyzer TBF-215 - Tanita)
|
baseline and 8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in central systolic blood pressure in mm/Hg at 8 weeks
Time Frame: baseline and 8 weeks
|
Before and after intervention with oscillometric monitoring system via BPLab
|
baseline and 8 weeks
|
Change from Baseline in Pulse Wave Velocity in meters/ second at 8 weeks
Time Frame: baseline and 8 weeks
|
Before and after intervention with oscillometric monitoring system via BPLab
|
baseline and 8 weeks
|
Change from Baseline in Fasting plasma glucose in mg/dL at 8 weeks
Time Frame: baseline and 8 weeks
|
Before and after intervention by spectrophotometry
|
baseline and 8 weeks
|
Change from Baseline in Total cholesterol in mg/dL at 8 weeks
Time Frame: baseline and 8 weeks
|
Before and after intervention by spectrophotometry
|
baseline and 8 weeks
|
Change from Baseline in Triglycerids in mg/dL at 8 weeks
Time Frame: baseline and 8 weeks
|
Before and after intervention by spectrophotometry
|
baseline and 8 weeks
|
Change from Baseline in High-density lipoprotein colesterol in mg/dL at 8 weeks
Time Frame: baseline and 8 weeks
|
Before and after intervention by friedewall formula
|
baseline and 8 weeks
|
Change from Baseline in Low-density lipoprotein colesterol in mg/dL at 8 weeks
Time Frame: baseline and 8 weeks
|
Before and after intervention by friedewall formula
|
baseline and 8 weeks
|
Change from Baseline in Alanine aminotransferase in IU/L at 8 weeks
Time Frame: baseline and 8 weeks
|
Before and after intervention by spectrophotometry
|
baseline and 8 weeks
|
Change from Baseline in Aspartate aminotransferase in UI/L at 8 weeks
Time Frame: baseline and 8 weeks
|
Before and after intervention by spectrophotometry
|
baseline and 8 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Fernando Grover-Páez, PhD, Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CUCS-INTEC-MV-UKN-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
Mayo ClinicCompleted
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Andalas UniversityHasanuddin University; Universitas Sumatera UtaraCompletedMetabolic Syndrome, Protection AgainstIndonesia
Clinical Trials on Conjugated linoleic acid/Leucine
-
University of JenaCognis Deutschland GmbH & Co. KGCompleted
-
University of Wisconsin, MadisonCompleted
-
University of Wisconsin, MadisonBunge Loders CroklaanCompleted
-
University of North CarolinaCognisCompleted
-
Ohio State UniversityCognisCompleted
-
Dartmouth-Hitchcock Medical CenterDartmouth CollegeCompleted
-
Dartmouth-Hitchcock Medical CenterNational Cancer Institute (NCI)TerminatedAdvanced Solid TumorsUnited States
-
Hamilton Health Sciences CorporationCompleted
-
University of ChesterCompletedInflammation | Obesity | Lipid Disorder | Lung FunctionsUnited Kingdom
-
Universidade Federal do Rio de JaneiroRio de Janeiro State Research Supporting Foundation (FAPERJ)CompletedInsulin Resistance | Blood Pressure | Oxidative Stress | Lipid Profile | Anthropometric MeasureBrazil